- Amended Statement of Changes in Beneficial Ownership (4/A)
01 Décembre 2009 - 6:19PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Expires:
February 28, 2011
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Ordemann Thomas
|
2. Issuer Name
and
Ticker or Trading Symbol
BioScrip, Inc.
[
BIOS
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
_____ 10% Owner
__
X
__ Officer (give title below)
_____ Other (specify below)
Executive Vice President
|
(Last)
(First)
(Middle)
100 CLEARBROOK ROAD
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
11/11/2009
|
(Street)
ELMSFORD, NY 10523
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
11/12/2009
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock, $.0001 Par Value
|
11/11/2009
|
|
S
|
|
41260
|
D
|
$8.5604
(1)
|
20250
|
D
|
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Option To Purchase Common Stock
|
$5.46
|
|
|
|
|
|
|
8/1/2008
(2)
|
8/1/2017
|
Common Stock, $.0001 Par Value
|
80000
|
|
80000
|
D
|
|
Option To Purchase Common Stock
|
$6.52
|
|
|
|
|
|
|
4/29/2009
(2)
|
4/29/2018
|
Common Stock, $.0001 Par Value
|
50625
|
|
50625
|
D
|
|
Option To Purchase Common Stock
|
$2.73
|
|
|
|
|
|
|
4/28/2010
(2)
|
4/28/2019
|
Common Stock, $.0001 Par Value
|
75000
|
|
75000
|
D
|
|
Explanation of Responses:
|
(
1)
|
Shares were sold at various prices between $8.49 and $8.60 per share. The reporting person undertakes to provide (upon request by the SEC staff, the issuer, or a security holder of the issuer) full information regarding the number of shares purchased or sold at each separate price.
|
(
2)
|
Vests and becomes exercisable in three equal annual installments commencing on the first anniversary of the date of grant.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Ordemann Thomas
100 CLEARBROOK ROAD
ELMSFORD, NY 10523
|
|
|
Executive Vice President
|
|
Signatures
|
/s/ Thomas Ordemann
|
|
12/1/2009
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024
Real-Time news about BioPlus Acquisition Corporation (NASDAQ): 0 recent articles
Plus d'articles sur